# Dose-finding Study of QGE031 as add-on Therapy to Evaluate Efficacy and Safety in Patients With CSU

> **NCT02477332** · PHASE2 · COMPLETED · sponsor: **Novartis Pharmaceuticals** · enrollment: 382 (actual)

## Conditions studied

- Chronic Spontaneous Urticaria

## Interventions

- **BIOLOGICAL:** QGE031
- **BIOLOGICAL:** Omalizumab
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT02477332
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-07-15
- **Primary completion:** 2016-11-02
- **Final completion:** 2017-06-12
- **Target enrollment:** 382 (ACTUAL)
- **Last updated:** 2021-01-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02477332

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02477332, "Dose-finding Study of QGE031 as add-on Therapy to Evaluate Efficacy and Safety in Patients With CSU". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT02477332. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*